GLP-1 Cost in 2027: What Wegovy, Zepbound and the Pill Really Cost Now

If you've tried to figure out what a GLP-1 actually costs lately, you've probably come away more confused than when you started — because the honest answer in late 2026 is "it depends, and it just changed." A year ago the story was simple and bleak: the branded drugs carried list prices north of a thousand dollars a month, insurance coverage was a coin flip, and the only cheap route was compounded. That whole picture got rewritten in 2026, fast, from several directions at once, and most of what's written online about GLP-1 pricing is now out of date.

This is the part of the GLP-1 story we care about most, because it's the part that actually decides whether you can get treatment. We built this site on a simple principle — that the number that matters is the real monthly price you'll pay at the dose you stay on, not the teaser on the landing page — and the 2026 shake-up is that principle on a national scale. So here's the current map: how much a GLP-1 really costs through each channel, who each one is for, where the traps are, and how to pay the least you honestly can. Where a figure comes from a manufacturer, a regulator, or a government program, we point you to the source, because in this topic a six-month-old price is often simply wrong.

Two orientation points before the detail. First, the prices below are a late-2026 snapshot, and several carry promotional end dates or step up after a few fills — we flag those, but the only reliable figure is the one you confirm today at the official source. Second, "cheapest" is never the whole question for a prescription you may take for years; stability, legitimacy and support matter too, which is exactly why we weigh them in our program rankings. With that said, let's talk numbers.

How much does a GLP-1 really cost in 2027?

Here's the direct answer, by channel, as the landscape stands heading into 2027 — ranges rather than single numbers, because your dose, your plan and the specific promo all move the figure.

• With good insurance coverage: as little as $0–$50 a month in copays when a plan covers the drug for weight loss — but coverage is exactly what's shrinking, and many plans require prior authorization.
• Medicare (via the GLP-1 Bridge), if eligible: a $50 monthly copay for covered weight-loss GLP-1s — a brand-new option in 2026 that didn't exist before.
• Manufacturer direct, self-pay: roughly $149 to $499+ a month depending on the drug and dose — for example, the Wegovy pill from around $149, the Wegovy injection around $349 (with a lower starter offer), and Zepbound vials from around $299. Far below the old list price.
• Compounded GLP-1s: still often $99–$299 a month, historically the cheapest route — but, as we'll explain, its price edge narrowed sharply and its legal footing changed.
• Branded at full list price with no coverage or program: the old $1,000+ a month figure you may remember — which, crucially, almost nobody needs to pay anymore given the direct options.

Sit with that range for a second, because it's genuinely strange: the same medicine, the same molecule in the same pen or pill, can cost one person nothing and another person a thousand dollars in the same month. That isn't how most products work, and it's the single most important thing to understand about GLP-1 pricing — the price isn't a property of the drug, it's a property of the path you take to it. Two neighbors on identical Zepbound doses can pay a $25 copay and $500 cash respectively, purely because one has coverage and the other is buying direct. Once you internalize that the number is about the channel, not the chemistry, the whole problem becomes tractable: your job isn't to find a cheaper drug, it's to find a cheaper door to the same drug.

That spread — from $0 to over a thousand dollars for the same class of drug — is the whole reason this guide exists. The difference between the top and bottom of that range isn't the medicine; it's which channel you use and how well you navigate it. The rest of this guide is about moving yourself toward the cheap end of that range legitimately. First, the three big shifts that created this new map.

How GLP-1 prices got so high — and started to fall

To navigate the new landscape, it helps to understand why the old one was so broken, because the forces that pushed prices to $1,000-plus are the same ones now, in reverse, pulling them down. This isn't a detour — it's what tells you whether a "deal" is real and where the next price drop comes from.

Why the list price was so high

The number you saw on a GLP-1 — well over a thousand dollars a month — was the list price, and almost nobody actually paid it, which is the first thing to understand about U.S. drug pricing. List prices are set high partly because the system runs on rebates: drug makers set a high sticker, then pay rebates to the pharmacy benefit managers (PBMs) who decide which drugs your insurance covers, and those rebates buy favorable placement on the formulary. The patient, meanwhile, often had their cost calculated off the inflated list price, especially before meeting a deductible. It was a system that worked badly for exactly the people paying cash — the uninsured and the self-pay buyer saw the worst possible number.

On top of that, GLP-1s are genuinely expensive to make (the injectable ones are peptides, complex to manufacture), demand was unprecedented, and for a while supply couldn't keep up — all of which gave manufacturers little reason to discount. The result was a drug millions of people needed, priced where only the well-insured could easily reach it, with compounded copies rushing into the gap.

What started the fall

Several forces converged in 2025–2026 to crack that open. Competition was the big one: more approved drugs (two makers, multiple products, then the pills) meant the makers had to compete on price for the first time. The compounded market embarrassed the list price — when patients could get the same molecule for $150, a $1,000 sticker looked indefensible. Direct-to-consumer channels let the makers sell around the PBM rebate game, offering a clean cash price instead of a rebate-inflated one. And political pressure on obesity-drug prices pushed the makers toward public commitments to lower what both cash patients and Medicare pay.

Put those together and you get the 2026 picture: a manufacturer-direct price of a few hundred dollars that bypasses the rebate machinery, a government program bringing Medicare in at a low copay, and a general downward drift. The high list price didn't come down so much as get routed around — the makers built new, cheaper doors rather than lowering the old one. That's why "where you buy" now matters so much: the expensive door and the cheap door lead to the same medicine.

The practical lesson from the mechanics: be skeptical of any price quoted against the list price ("80% off!"), because the list price was always fiction for most buyers. Judge a price on its absolute number at your maintenance dose, compare it across the direct, insured and Medicare channels, and remember that the forces pushing prices down — competition and direct sales — are still in motion.

Shift #1: Employer coverage is retreating

Start with the bad news, because it's what's pushing a lot of people to read a guide like this. After three years of expanding, employer coverage of GLP-1s for weight loss declined for the first time in 2026. A widely-cited survey of close to 500 companies found the share covering these medications for weight loss fell to roughly 53%, and — more worrying for anyone currently covered — a significant minority of the employers who still cover them said they're considering dropping that coverage. Reporting through late October 2026 framed it plainly: fewer U.S. employees will have GLP-1 weight-loss coverage in 2027.

Why are employers pulling back? Cost, mostly. GLP-1s are expensive in aggregate, a lot of employees want them, and for a self-insured company that math adds up fast — especially when people take the drugs long-term, as the condition usually requires. Some employers added hurdles (prior authorization, BMI thresholds, step therapy) rather than cutting entirely; others are exiting weight-loss coverage while keeping coverage for diabetes, where the same drugs have older, firmer insurance footing.

There's a deeper tension underneath the employer pullback worth naming, because it shapes where coverage goes next. Obesity medicine is increasingly understood as treatment for a chronic disease, not a cosmetic add-on — the same framing that justifies covering blood-pressure or cholesterol drugs. But GLP-1s are expensive and a large share of the workforce wants them, so employers are caught between the medical case for coverage and a budget that treating everyone would strain. The result is the uneven, shifting patchwork you see: some employers leaning into coverage as real healthcare, others retreating on cost, and many landing on hurdles as a compromise. Which way the balance tips over the next few years depends on whether prices keep falling enough to make broad coverage affordable — another reason the downward price trend matters so much.

Here's the part the alarming headlines miss, though, and it's the thread of this whole guide: losing employer coverage in 2026 lands far more softly than it would have in 2024, because the fallback options got dramatically cheaper at the same moment. A year ago, "my employer dropped GLP-1 coverage" meant a jump to a $1,000-plus list price or nothing. Now it means stepping onto a manufacturer-direct price of a few hundred dollars, or — if you're Medicare-eligible — a $50 copay. That's a real cost increase if you were paying a low copay, and it stings; it is not the cliff it once was.

If you're facing a coverage loss for the 2027 plan year, the practical moves are: check exactly what your (or your spouse's) plan will and won't cover for next year during open enrollment; find out whether your drug is covered for a diabetes indication if that applies to you; and price the direct and Medicare routes below before you panic. Our section on what you'll pay by situation walks through the coverage-loss case specifically.

Shift #2: Direct self-pay prices collapsed

This is the shift that changed everything, and it's the one most people haven't fully absorbed. In 2026 the drug makers began selling their GLP-1s directly to patients at self-pay prices a fraction of the old list price, through their own pharmacies and a federal direct-purchase site — a response both to competition (including from compounders) and to political pressure to bring obesity-drug prices down.

The concrete result, as of late 2026, is that a cash-pay patient can buy the FDA-approved branded drugs for roughly the following, direct from the manufacturers' official channels:

• Wegovy pill (oral semaglutide): from about $149/mo at the lowest dose, rising with dose (roughly $149 / $199 / $299 by strength).
• Wegovy injection: around $349/mo at standard doses, with a lower starter offer near $199/mo for the first couple of fills that runs through the end of 2026.
• Zepbound (tirzepatide): vials from about $299/mo at the starting dose, rising with dose (into the $400–$700 range at higher doses).
• Foundayo (orforglipron, the newer pill): priced in a similar self-pay range to the other oral option.

Compare that to the $1,000-plus monthly list price these drugs carried not long ago, and you can see why this is the headline. For a self-pay buyer, the FDA-approved drug — with its oversight, consistent dosing and fixed-dose pens — is now within a few hundred dollars a month, and in some cases genuinely competitive with compounded. The most reliable place to confirm current self-pay pricing is the manufacturer's own site — NovoCare for Wegovy and the official Zepbound site for Zepbound — because these prices and promotions change, and a federal direct-purchase site also lists manufacturer self-pay prices.

Two catches to keep in mind, both of which we'll return to. First, several of these are promotional or starter prices with expiry dates or fill limits — the attractive $199 Wegovy starter, for instance, applies to the first couple of fills and then steps up, so the price you pay in month four is the one that matters. Second, these are self-pay prices: they don't run through insurance, so they don't count toward a deductible or out-of-pocket maximum. For many people that's fine; for someone with a plan that would eventually cover the drug, it's a trade-off worth doing the math on.

What employers are doing instead — and your moves

If your employer is pulling back on GLP-1 coverage, it helps to know what they're actually doing, because "dropping coverage" takes several forms and each leaves you a different play.

Adding hurdles rather than cutting. Many employers aren't eliminating coverage outright — they're tightening it with prior authorization, higher BMI thresholds, step therapy (try a cheaper option first), or requiring participation in a lifestyle program alongside the drug. If that's your situation, coverage still exists; you just have to clear the gates. Find out the exact 2027 requirements and work with your clinician to meet them.

Keeping diabetes, cutting weight loss. A common split: the employer keeps covering the GLP-1 molecules for type 2 diabetes (where they're long-established) while dropping the weight-loss indication. If you have diabetes or prediabetes, this matters — the diabetes path may remain covered.

Shifting to allowances or different benefit structures. Some employers are moving toward arrangements where you get a healthcare allowance to buy your own coverage, or carving obesity care into a separate (sometimes more limited) program. Read what's actually replacing the old benefit before assuming it's nothing.

Dropping it entirely. Some will simply exit weight-loss drug coverage. That's the hardest case, and it's where the rest of this guide earns its keep — the manufacturer-direct and Medicare routes are your fallback, and they're far cheaper than the pre-2026 alternative.

One nuance worth knowing if you're comparing jobs or plans: because coverage is now so uneven, GLP-1 benefits have quietly become a real differentiator between employers and between plans. Two plans with similar premiums can differ by thousands of dollars a year for someone who needs a GLP-1, depending purely on whether and how they cover it. If this medication matters to your household, it's worth treating GLP-1 coverage as a line item when you weigh plans during open enrollment — or even when you weigh a job offer — rather than discovering the gap in January. The benefit that used to be background is now, for a lot of families, a number worth optimizing around.

Your concrete moves when coverage changes: during open enrollment, compare every plan available to you (and your spouse's plans) on how they handle GLP-1s for 2027, not just premiums; ask HR or the benefits portal for the specific formulary and requirements rather than guessing; check whether a diabetes indication applies; and price the direct and Medicare routes in advance so a coverage loss is a planned step-down, not a scramble. The worst outcome is finding out in January that your drug isn't covered and having no plan B priced — which, after reading this, won't be you.

Shift #3: Medicare started covering weight-loss GLP-1s

The third shift is the one that was supposed to be impossible: Medicare, which had long been barred from covering drugs used purely for weight loss, began covering GLP-1s for weight management in 2026 through a new program called the Medicare GLP-1 Bridge.

Here's what it is, in plain terms. The Bridge is a federal demonstration program, run by the Centers for Medicare & Medicaid Services, that began on July 1, 2026 and lets eligible Medicare Part D enrollees get covered weight-loss GLP-1s for a $50 monthly copay. The covered products include the Wegovy pill and injection, the Zepbound KwikPen, and the Foundayo pill, when prescribed for weight management. For a population that previously had no Medicare route to these drugs for weight loss, $50 a month is a dramatic change. Details of the program are laid out by CMS, and general Medicare coverage information lives at medicare.gov.

The fine print matters here, and it's exactly the kind of thing that's easy to get wrong, so verify your own situation rather than assuming:

• It's a copay, with conditions. The $50 is separate from your regular Part D benefit — notably, it generally doesn't count toward your Part D deductible or yearly out-of-pocket limit.
• Eligibility is specific. It's aimed at enrollees with obesity (or overweight plus certain weight-related conditions), generally requires prior authorization, and sources indicate people who already filled a GLP-1 through their Part D plan earlier in the year may not be eligible to switch into the Bridge in that same year. The precise criteria are a CMS matter — confirm yours.
• It's a demonstration with a time limit. The Bridge is a pilot, not a permanent benefit. Its end date has already moved once (reporting has cited both end-2026 and end-2027 depending on extensions), so treat it as "available now, confirm how long."

The Bridge sits on top of a broader deal in which the manufacturers agreed to lower the price Medicare pays for these drugs (figures around $245 a month have been reported). For an individual, though, the number that matters is the $50 copay if you qualify — and if you're on Medicare and carrying excess weight, this is worth a specific conversation with your prescriber and plan, because it may be the cheapest legitimate route available to you.

Practically, getting onto the Bridge means confirming your Part D plan is participating, having your prescriber document that you meet the clinical criteria and submit the prior authorization, and being prescribed one of the covered products for weight management. It's more paperwork than walking into a pharmacy, but it's the same kind of paperwork that unlocks any covered medication, and the payoff — a $50 copay on a drug that had no Medicare route a year ago — is large. If you're newly eligible, don't assume it happens automatically; it's something you and your prescriber initiate. And because it's a demonstration that has already had its timeline adjusted once, check its current status when you start rather than relying on a date you read somewhere months earlier.

Every channel compared: what you pay, who it's for, the catch

Here is the whole landscape in one view. Find the row that matches your situation, then read the catch column carefully — that's where the real decision lives.

*Late-2026 snapshot in U.S. dollars; ranges depend on drug, dose, plan and promotions, several of which have expiry dates. Confirm the current figure at the manufacturer's official site, with your insurer, or with CMS before you buy. This is general information, not financial or medical advice.

What each drug costs

Zooming into the specific medications, because "a GLP-1" isn't one price — it varies a lot by which drug and, within each, by dose. All figures below are late-2026 self-pay/direct ballparks unless noted; insurance or the Medicare Bridge can take them far lower.

Wegovy (semaglutide) — injection and pill

Wegovy now comes in two forms, and the pill is the cheaper entry. The oral Wegovy pill runs from roughly $149/mo at the lowest dose up to around $299 at higher strengths. The Wegovy injection sits around $349/mo at standard doses direct from the manufacturer, with a lower starter offer (near $199/mo for the first couple of fills) that's scheduled to end with 2026. Confirm both at NovoCare. Covered by insurance or the Medicare Bridge, your cost can drop to a copay.

Zepbound (tirzepatide)

Zepbound, generally the most effective option on weight loss, is priced by dose. Direct self-pay vials start around $299/mo at the lowest dose and climb into the $400–$700 range at higher doses; the KwikPen is also covered under the Medicare Bridge. Check current pricing at the official Zepbound site. Our tirzepatide vs semaglutide guide covers how it compares clinically.

Ozempic and Mounjaro (the diabetes brands)

These are the same molecules (semaglutide and tirzepatide) branded for type 2 diabetes. If you have diabetes, these are often where insurance coverage is firmest and most durable, even as weight-loss coverage retreats — so for a diabetic patient, the diabetes indication can be the most affordable path. They are not FDA-approved for weight loss specifically, so using them for that is a clinical decision for your prescriber.

Foundayo (orforglipron) — the newer pill

The newest FDA-approved oral option is priced in a similar self-pay range to the other pill and is covered under the Medicare Bridge. Because it's a small-molecule drug that's cheaper to manufacture, it carries the best long-term prospect of falling prices. Our guide to the GLP-1 pill covers how it stacks up against oral and injectable semaglutide.

How the direct channels actually work (and how to order safely)

"Buy direct from the manufacturer" sounds simple, but people get tripped up — both by the mechanics and by fake sites riding the trend. Here's how the legitimate direct channels work and how to use them without getting burned.

The manufacturer pharmacies

Both makers run official direct-to-patient channels: Novo Nordisk's is NovoCare (for Wegovy), and Lilly's is LillyDirect (for Zepbound), each with its own pricing pages. The basic flow is the same: you still need a valid prescription from a licensed clinician, but instead of the drug routing through the usual insurance-and-pharmacy chain at a rebate-inflated price, you buy at a set self-pay price and it ships to you. Some offer their own telehealth path to get the prescription; you can also bring a prescription from your own clinician. The key advantage is a clean, published cash price for the FDA-approved product — no PBM, no mystery.

The federal direct-purchase site

A federal direct-purchase website launched in 2026 that aggregates manufacturer self-pay prices for a range of drugs, GLP-1s among them, as part of the broader push to lower obesity-drug costs. In practice it points you toward the same manufacturer self-pay prices; for actually confirming the current number and ordering, the manufacturer's own official site is the authoritative source. We mention the federal channel because you'll see it referenced, not because it changes the underlying price you'll pay.

Why do the makers sell direct at all, when it competes with their own insured channel? Because the direct price sidesteps the rebate machinery that inflated list prices, lets them capture the large and growing cash-pay market (including everyone losing employer coverage), and answers the political and competitive pressure on obesity-drug prices with a clean, defensible number. For you, the motive matters less than the result: a legitimate, FDA-approved drug at a published price you can see before you buy, without a PBM in the middle. That transparency is itself worth something in a market this murky — you're comparing a real number to a real number, which is more than the insured channel often lets you do.

Ordering safely

The direct-pricing boom created a predictable side effect: fake "official" sites and lookalikes hoping to catch people searching for cheap Wegovy or Zepbound. Protect yourself with a few habits. Start from the manufacturer's real domain — reach NovoCare and the official Zepbound/LillyDirect pages by typing the known address or following a link from the drug's official site, not from an ad or a search result you're unsure of. A real channel still requires a prescription — any "direct" site selling an injectable GLP-1 with no prescription is not legitimate. Be wary of prices well below the manufacturer's own — the maker is not undercut by a random third party on its own FDA-approved drug. And check that payment and site security look right before entering card details. The legitimate direct price is a genuinely good deal; the fake version of it is a way to lose money or receive something dangerous.

Confirm current official pricing at NovoCare (Wegovy) and the official Zepbound site (Zepbound), and if a telehealth program offers to handle the prescription, apply the same vetting we lay out in how to spot a legit online clinic.

The compounded question: cheaper, but the gap shrank

For most of the last three years, the answer to "what's the cheapest GLP-1?" was simple: compounded. During the shortage, compounded semaglutide and tirzepatide sold for a fraction of the branded list price, and that price gap built an entire telehealth industry. Two things changed that in 2026, and both matter for your wallet.

First, the branded price fell toward the compounded price. When direct self-pay Wegovy and Zepbound dropped to a few hundred dollars a month, the compounded discount stopped being a chasm and became a gap — sometimes a modest one. A compounded program at $149–$199 and a manufacturer-direct branded drug at $299–$349 are in genuinely comparable territory now, and once you factor in the branded product's FDA oversight, consistent dosing and fixed-dose pens, "a bit cheaper" compounded is a weaker argument than it was when the gap was $900.

Second, the legal ground under compounded shifted. The FDA declared the semaglutide and tirzepatide shortages resolved (tirzepatide in December 2024, semaglutide in February 2025), which ended the broad, shortage-based permission that made mass-market compounding legal. Legitimate compounding continues in narrow, patient-specific circumstances, but the cheap "one formula for everyone" model now rests on contested legal ground. We cover this in depth in is compounded semaglutide still legal? — essential reading if the compounded price is what's drawing you.

So where does that leave compounded on pure cost? Still often the lowest sticker price, yes — but the decision is no longer "cheap compounded vs. unaffordable branded." It's "slightly-cheaper compounded on shakier legal and quality footing vs. a now-affordable, FDA-approved branded drug." For some people with a genuine clinical reason, or without any coverage and on a tight budget, a legitimate compounded program still makes sense. For many others, the 2026 price drops flipped the default toward branded. Run your own numbers with current prices; the old assumption that compounded is dramatically cheaper no longer holds automatically.

There's also a hidden cost to compounded that the sticker doesn't show: the risk that your supply changes under you. Because the legal footing narrowed, a compounded program may have to alter your formula, raise prices, or stop offering the product as rules tighten — and an interruption to a GLP-1 isn't free either, since appetite and weight tend to rebound when treatment stops abruptly. A branded drug at a stable, published direct price doesn't carry that particular risk. When you compare, factor in not just this month's price but the odds that this month's price is still available in six months. In a year when branded got cheap and compounded got legally shakier, that stability has real, if hard-to-quantify, value — and for a lot of people it tips a close price comparison toward the FDA-approved option.

What you'll really pay, by situation

General ranges only get you so far; the real question is what you will pay given your specific circumstances. Find yourself below.

You have employer or commercial insurance that covers it

Best case, you're looking at a copay — potentially $0–$50/mo — which beats every other route. Your job is to confirm it's still covered for weight loss in the 2027 plan year (coverage is the thing shrinking), clear any prior authorization, and use a manufacturer savings card if eligible to cut the copay further. Don't assume last year's coverage carries over; check during open enrollment.

You're losing coverage for 2027

Don't panic — this is the situation the 2026 price drops rescued. Price the manufacturer-direct route (a few hundred dollars a month for branded, less for the pills), check whether a diabetes indication applies to you, and if you're near Medicare eligibility, look at the Bridge. The gap between a low copay and direct self-pay is real, but it's hundreds of dollars, not the thousand-dollar cliff it used to be. Our what you'll really pay guide helps you model it.

You're on Medicare

The GLP-1 Bridge's $50 copay is likely your cheapest legitimate route if you're eligible — obesity or overweight-plus-a-condition, with prior authorization. Raise it specifically with your prescriber and Part D plan, and confirm current eligibility and the program's end date with CMS, since it's a time-limited demonstration.

You're uninsured or paying cash

Your realistic options are manufacturer-direct branded (now a few hundred a month, and FDA-approved) or a legitimate compounded program (often a bit less, but not FDA-approved and on narrower legal footing). The pills are the cheapest branded entry. Compare the real monthly price at your maintenance dose across both, and weigh the compounded trade-offs honestly — the program comparison shows each option's true cost.

You have type 2 diabetes

You may have the most durable, affordable path of all: coverage for the diabetes brands (Ozempic, Mounjaro) tends to be firmer and is less affected by the weight-loss coverage pullback. Work with your clinician on the right drug for your diabetes, and the weight benefit often comes along with it.

Three worked examples: what a year actually costs

Ranges are useful; concrete math is clearer. Here are three realistic scenarios with the year-one arithmetic spelled out, using late-2026 figures. These are illustrative — your real numbers depend on your drug, dose, plan and current promos — but they show how differently the same decision plays out by situation, and how to do the math yourself.

Example 1: Self-pay, wants the pill, no coverage

Maria has no GLP-1 coverage and wants to avoid injections, so she prices the Wegovy pill direct. She starts at the lowest dose (~$149/mo) and titrates up over a few months to a maintenance dose around the middle tier (~$199–$299/mo). A realistic year-one estimate: roughly three months at the lower tiers and nine at maintenance lands her somewhere in the $2,500–$3,200 range for the year, all-in, FDA-approved, no insurance friction. Had she assumed the old list price, she'd have braced for $12,000-plus — the direct channel cut her expected cost by roughly three-quarters. Her watch-outs: the price steps up with dose, and she should re-check for lower offers each quarter.

Example 2: Losing employer coverage going into 2027

James had a $25 copay through work; his employer is dropping weight-loss GLP-1 coverage for 2027. His instinct is panic — he remembers the $1,000 price. In reality, he prices Zepbound direct (he wants the strongest option) at roughly $299–$499/mo depending on his dose, so his year-one self-pay cost lands in the rough $4,000–$6,000 range — a real increase from ~$300/year in copays, but far from the ~$12,000 cliff he feared. His better moves: check whether his spouse's plan covers it for 2027, confirm he doesn't qualify for a diabetes indication, use any manufacturer savings, and consider whether the pill at a lower price would meet his needs. The coverage loss costs him a few thousand dollars a year, not a path to treatment.

Example 3: On Medicare, newly eligible for the Bridge

Linda is 68, on Medicare Part D, with obesity and high blood pressure. Before 2026 she had no Medicare route to a weight-loss GLP-1 at all. Through the Medicare GLP-1 Bridge, with prior authorization, she pays the $50 monthly copay — about $600 for the year — for a covered product like the Wegovy pen or Foundayo. The catches she confirms: the $50 doesn't count toward her Part D out-of-pocket max, she needs prior authorization, and the Bridge is a time-limited pilot she'll need to watch for renewal. For her, it's by far the cheapest legitimate route, and it simply didn't exist a year earlier.

Example 4: Type 2 diabetes with stable coverage

David has type 2 diabetes and carries excess weight. His plan still covers the GLP-1 molecule for his diabetes — that coverage wasn't touched by the weight-loss pullback — so he pays a tier copay, say $25–$60/mo, for a diabetes brand like Ozempic or Mounjaro, and the weight benefit comes along with the glucose control. His year-one cost lands around $300–$700, among the most affordable paths of anyone here, precisely because the diabetes indication sits on firmer insurance ground. His only real task is working with his clinician on the right drug for his diabetes; the affordability largely takes care of itself. For the large number of people with both diabetes and excess weight, this is the quietly cheapest route, and it's one the weight-loss-coverage headlines tend to obscure.

The throughline across all four: the same class of drug, bought different ways, produces wildly different annual costs — roughly $300–$700, $600, $2,500–$3,200, and $4,000–$6,000 — and in every case the figure is far below the old list-price nightmare. The money is made or lost in matching the channel to your situation and doing the month-by-month math at your maintenance dose, which is exactly the calculation our what you'll really pay guide walks through.

The hidden costs and traps (where the real number hides)

The sticker price is where programs compete; the hidden costs are where budgets break. These are the things that turn an advertised price into a very different bill, and spotting them is most of what separates a good deal from a regret.

• The intro/starter teaser. This is the biggest one, and it's everywhere — "$39 first month," the $199 Wegovy starter, the low compounded intro. These apply to the first fill or two and then step up. The number that matters is what you'll pay in month four, at your maintenance dose, not month one. Always multiply out the ongoing price.
• Dose escalation. GLP-1s are titrated up over months, and many pricing tiers rise with the dose. A price quoted at the starting dose can be meaningfully higher once you reach the dose that actually controls your appetite. Ask what the top-dose price is before you commit.
• Promo expiration dates. Several 2026 direct offers have hard end dates (the Wegovy starter price, for example, is tied to end-2026). A price that's real today may not be real next quarter — check the expiry, not just the number.
• Self-pay vs. deductible. Manufacturer-direct and compounded prices are self-pay, so they don't count toward your insurance deductible or out-of-pocket maximum. If you have a plan that would eventually cover the drug after the deductible, paying cash on the side can mean paying twice in a sense — do that math.
• Prepay bundles. Multi-month prepay lowers the monthly rate but bets on the provider shipping reliably for all those months — and, for compounded, on the legal situation holding. Weigh the discount against the refund terms and the lock-in.
• Membership + medication split. Some programs quote a low membership fee and bill medication separately; the "price" you saw was only half the bill. Add both before comparing.
• Shipping, labs and visit fees. Usually small, sometimes not, occasionally hidden. Ask what's included.

Our whole pricing methodology is built around dodging exactly these traps: we publish each program's real monthly cost at a maintenance dose, not the teaser, which is the comparison that actually predicts your bill. See before you prepay for the prepay-specific checklist.

How to pay the least (a step-by-step)

Whatever your situation, work through these in order — each step can knock a chunk off, and most people skip at least one.

1. Check your current coverage properly. Call your plan or read the 2027 formulary: is your specific drug covered for weight loss, at what tier, with what prior-authorization requirement? If you have diabetes, check the diabetes brands separately — they're often covered when weight-loss versions aren't.
2. If eligible, pursue the Medicare Bridge. For Medicare enrollees, the $50 copay is likely the floor. Confirm eligibility and get the prior authorization started with your prescriber.
3. Clear prior authorization, and appeal denials. Many denials are reversed on appeal with the right documentation (BMI, weight-related conditions, prior attempts). Don't treat a first "no" as final — ask your clinician's office to help appeal.
4. Use manufacturer savings cards. If you have commercial insurance, savings cards can cut copays substantially; if you're self-pay, the manufacturer-direct price is itself the savings program. Check NovoCare and the Lilly/Zepbound site.
5. Compare manufacturer-direct vs. compounded on the real ongoing price. With branded prices down, run both at your maintenance dose. Factor in the compounded legal/quality trade-offs, not just the sticker.
6. Consider the pill. The oral options are the cheapest branded entry point and skip the needle — worth pricing if an injection isn't essential for you.
7. Use pre-tax dollars. If you have an HSA or FSA, prescription GLP-1s are typically eligible, which effectively discounts the price by your tax rate — one of the simplest savings most people leave on the table.
8. Re-check periodically. This market is moving fast and generally downward; the cheapest route today may not be the cheapest in six months. Set a reminder to re-shop.

Work those in order and most people land several hundred to several thousand dollars a year below where they'd be if they'd simply taken the first price offered. The ones who overpay aren't careless — they're busy, and they assumed the system would surface the best price for them. It won't; in U.S. drug pricing, the cheapest path is almost never the default one, and the savings go to whoever does the comparison. That's the single most valuable habit in this whole guide: treat the price as something you actively shop, not something you're quoted and accept.

A quick word on insurance and prior authorization

If you're going the insurance route, prior authorization is the gate you'll most often hit, and understanding it saves money and weeks. Prior authorization means your insurer wants documentation that you meet their criteria before they'll cover the drug — typically a qualifying BMI, sometimes a weight-related condition, sometimes evidence you've tried other approaches. It's paperwork, and it's often where coverage quietly dies not because you don't qualify but because the form didn't get done right.

Two things help. First, a program or clinician's office that handles prior authorization well is worth real money — it's one of the things we look at in reviews, because a program that just mails you a denial is leaving your coverage on the table. Second, denials are frequently overturned on appeal; if you're denied, ask your prescriber to submit an appeal with full documentation of your BMI, any related conditions, and prior weight-loss attempts. People give up at the first denial far too often, and it can cost them a covered drug they were entitled to. If insurance is your route, treat prior authorization and appeals as part of the process, not an afterthought.

If an internal appeal fails, you usually aren't out of options. Most plans are required to offer an external review — an independent third party reconsiders the denial — and your state insurance regulator can often help if you believe a denial was improper. These steps take persistence and weeks, not minutes, but for a medication you may take for years, a successful appeal that unlocks a copay price can be worth thousands of dollars over time. The asymmetry is stark: a few hours of paperwork against years of a lower price. That's a trade worth making, and it's exactly the kind of unglamorous, high-value legwork that the best programs do on your behalf and the worst ones quietly skip.

Pricing red flags: how to spot a GLP-1 cost scam

Any time a product is in high demand and prices are confusing, scammers move in — and GLP-1s check both boxes. The same search for a cheaper price that leads to a legitimate deal can lead to a fraud or a dangerous counterfeit. Here's how to tell them apart.

• No prescription required. The brightest red flag. Legitimate GLP-1s — branded or legitimately compounded — require a prescription from a licensed clinician. A site selling injectable semaglutide or tirzepatide with no medical review is not a bargain; it's a danger sign.
• Prices below the manufacturer's own direct price. The makers set the floor on their FDA-approved products. A third-party site advertising brand-name Wegovy or Zepbound well under the official direct price is selling something that isn't what it claims — counterfeit, diverted, or nonexistent.
• "Research peptides" / "not for human use." Not a budget version of the drug — unregulated material of unknown identity and purity, illegal to use as medicine, and genuinely hazardous. We cover this in our compounded legality guide.
• Overseas pharmacies with no verifiable licensing. Importing from an unverified overseas seller carries real risk of counterfeits and no recourse. Legitimate savings don't require leaving the regulated system.
• Pressure and urgency. "This price expires in 10 minutes," heavy pressure to prepay a year up front, or aggressive upsells are marketing red flags that often accompany the other problems.
• Lookalike "official" sites. Fake pages mimicking NovoCare, LillyDirect or a pharmacy, reached through an ad or a stray search result. Start from the manufacturer's known domain instead.

It's worth naming why the scam risk rose precisely as the legitimate prices fell, because the two are connected. When the whole internet is searching for "cheaper Wegovy," fraudsters know exactly what bait to use, and a fake "$99 brand-name Zepbound, no prescription" ad converts because it sounds like just another entry in a confusing market of real discounts. The confusion is the cover. Your defense is a simple mental rule that cuts through it: the legitimate floor is the manufacturer's own direct price, reached through a prescription. Anything claiming to beat that floor on an FDA-approved product, or to skip the prescription, is not a better deal — it's a different and worse thing wearing the deal's clothes. Hold that rule and the scams mostly fail to land, no matter how the market churns around them.

The reassuring flip side: the legitimate cheap routes in 2026 are genuinely cheap, so you don't need to take these risks to get a fair price. A real prescription, a verifiable pharmacy or manufacturer channel, and a price at or around the official direct figure is how you save money safely. If an offer beats that by a lot and trips any flag above, the right move is to walk — the downside isn't just losing money, it's injecting something unknown.

Understanding your insurance: formularies, tiers, and step therapy

If you're chasing insurance coverage — still the cheapest route when you can get it — a little fluency in how drug benefits work saves real money, because coverage rarely means "they just pay." It means navigating a few specific mechanisms, each of which can be a dead end or a door.

The formulary and tiers. Your plan's formulary is its list of covered drugs, sorted into tiers that determine your copay. A GLP-1 might be on a high tier (bigger copay), a low tier (smaller), or excluded entirely for weight loss. Two plans that both "cover Wegovy" can leave you paying very different amounts. During open enrollment, look up your specific drug on the specific plan's formulary for the coming year — not this year's, since weight-loss coverage is the thing being cut.

Prior authorization. Covered in brief earlier, but worth repeating as a mechanism: it's the documentation gate, usually requiring a qualifying BMI and sometimes related conditions or prior attempts. It's where a lot of coverage quietly dies on paperwork rather than merit. A clinician's office that does this well is worth money.

Step therapy. Some plans require you to try (and fail) a cheaper option first — an older medication, or a lower-cost GLP-1 — before they'll cover the one your clinician prefers. It's frustrating and sometimes clinically questionable, but knowing it's there lets you plan for it rather than get blindsided.

The PBM behind the curtain. Your actual coverage decisions are usually made by a pharmacy benefit manager, not the insurer's logo on your card. That's invisible to you day-to-day, but it's why coverage can seem arbitrary and why rebates (not patient benefit) drive a lot of formulary placement. You can't change it, but understanding it explains why the direct-to-consumer cash price sometimes beats your "covered" price after a high deductible — a comparison always worth running.

The practical takeaway: before you assume insurance is your cheapest route, actually price it — your tier copay, whether you've met your deductible, and any prior-auth or step-therapy hurdles — against the manufacturer-direct cash price. Sometimes covered wins easily; sometimes, especially early in a plan year with a high deductible, the cash price is lower. The only way to know is to compare the two for your specific plan, which almost nobody does.

Where prices go from here

Nobody can promise future prices, but the direction of travel in late 2026 is clearer than it's been, and it mostly favors buyers.

The trend is downward. The manufacturer deals that lowered the price Medicare pays included a path toward further reductions over the next couple of years (figures around $245 a month and falling have been reported as targets), and direct self-pay prices have been drifting down, not up. Competition is the engine: more approved drugs, more channels, and political pressure on obesity-drug prices all push the same way.

The pill changes the math. Oral GLP-1s — especially small-molecule orforglipron (Foundayo), which is cheaper to manufacture than the injectable peptides — carry the best structural case for lower prices over time. As oral competition grows, it should pull the whole category's prices down further.

The next wave of drugs is already pushing in. Beyond today's options, a deeper pipeline is coming — newer and more powerful agents, and different mechanisms (amylin-based drugs and triple-hormone agonists among them) are in development, some reporting strong results with gentler side effects. More competitors chasing the same enormous market is the surest force for lower prices there is; each new approval gives buyers another option and gives the incumbents another reason to discount. The injectable-peptide monopoly on effective weight loss is ending, and that erosion of pricing power generally flows to the patient.

Coverage is the wild card. Employer coverage retreating cuts the other way, and whether the Medicare Bridge becomes permanent or expires is genuinely unsettled. So the likely shape of the next couple of years is: self-pay prices keep easing, more affordable branded options appear, but insurance coverage stays patchy — which makes knowing how to navigate the direct and government channels more valuable, not less.

One caution against over-optimism, though: "trending down" is not "cheap for everyone," and the gains are uneven. The self-pay buyer and the Medicare-eligible patient won big in 2026; the person who lost a generous employer copay went the other way. And prices falling toward a few hundred dollars a month still leaves a medication that's out of reach for plenty of households, especially as a long-term, likely-permanent expense. Progress is real and worth stating plainly, but so is the gap that remains. The honest position is neither "GLP-1s are affordable now" nor "they're still a thousand dollars" — it's that the floor dropped dramatically, the options multiplied, and whether you benefit depends on knowing how to reach them.

The honest forecast: the thousand-dollar GLP-1 is already effectively dead for anyone who shops, and the floor is still dropping. The skill worth having isn't predicting the exact price — it's knowing the channels and re-checking them, because in a falling, fragmenting market the person who re-shops pays far less than the person who set up autopay in 2024 and never looked again.

What this means for choosing a program

All of this reshapes how to pick an online weight-loss program, because the cost landscape is now a moving target and the right program is one that navigates it for you rather than locking you into yesterday's deal.

A few principles follow directly from the 2026 shifts. Favor flexibility: a program that can move you between compounded and branded, offer the pills, and help with insurance is worth more now that any single channel can change under you. Weight insurance and prior-authorization help heavily if you have coverage worth chasing — a program that actually works your prior auth and appeals can save you more than a cheaper program that doesn't. Read the real ongoing price, not the intro — more important than ever with so many starter promos in play. And be wary of lock-in: in a falling-price market, a long prepay on a single contested product is a bet against your own future options.

This is exactly what our ranked comparison is built to surface — we score programs on value (the real price, not the teaser), clinical and insurance support, medication flexibility, and transparency, precisely because those are the things that determine your actual cost and experience in a market this volatile. Pair this guide with our complete guide to GLP-1 weight loss online and our scoring methodology to match a program to your situation.

The cost-versus-value question: is it worth it?

A cost guide that only counts the outflow is only half honest, so it's worth asking the harder question directly: is a few hundred dollars a month — a few thousand a year — worth it? This is a personal and medical decision, not one we can make for you, but a few points help you weigh it clearly rather than just flinching at the number.

Weigh it against what obesity itself costs. Excess weight drives a long list of expensive, serious conditions — type 2 diabetes, heart disease, sleep apnea, joint problems and more (our guide to what GLP-1s do beyond weight loss covers the proven ones). Effective treatment can reduce those downstream costs and risks, which means the drug's price isn't a pure expense; for some people it offsets other medical spending and, more importantly, buys health. That doesn't make it cheap, but it reframes "a few thousand a year" as an investment against conditions that cost far more.

Account for the whole program, not just the molecule. The medication is one line item; the support around it — clinical oversight, coaching, titration help — affects whether you actually get results and keep them. The cheapest drug attached to no support can be worse value than a slightly pricier program that helps you succeed, because a GLP-1 you quit early is money spent for little lasting benefit.

Factor in the long term. These are, for most people, long-term treatments — stopping tends to bring weight back. So the honest budgeting question isn't "can I afford one month" but "can I sustain this, and what's my plan if a promo expires or coverage changes." Building a realistic long-term cost picture, using the maintenance price and not the teaser, is the responsible way to decide — and it's a reason the falling-price trend matters so much, because it makes long-term treatment sustainable for more people.

It also helps to compare the drug's cost to what people already spend chasing weight loss less effectively — the gym memberships that go unused, the meal plans and supplements and programs that rarely produce double-digit weight loss. That's not an argument that a GLP-1 is cheap; it's a reminder to judge the spend against the alternatives you'd actually pursue, not against zero. For someone who has spent years and real money on approaches that didn't work, a medication that does — at a few hundred dollars a month that keeps falling — can be a more rational allocation than it first appears, even before counting the downstream health savings.

None of this is a push to spend. For some people the honest answer is that the cost doesn't fit the budget right now, and there are lower-cost legitimate routes (the pills, the Medicare Bridge, covered diabetes indications) worth exhausting first. The point is to make the decision with the full picture — the cost set against the value and the alternatives — rather than reacting to a sticker price in isolation.

Myths about GLP-1 costs, corrected

The pricing confusion has bred a crop of myths that cost people money. Here are the ones worth correcting.

Myth 1: "GLP-1s cost over $1,000 a month."

That's the list price, and almost nobody needs to pay it anymore. Manufacturer-direct self-pay is a few hundred a month, insurance can mean a copay, and the Medicare Bridge is $50 for those eligible. Quoting the list price as "the cost" is the single most outdated claim in this topic.

Myth 2: "Compounded is always way cheaper."

It was during the shortage; the gap shrank hard in 2026 when branded direct prices fell. Compounded is often still a bit cheaper, but "a bit" now, not "a fraction" — and it comes with narrower legal footing and no FDA approval. Re-run the comparison; the old assumption often no longer holds.

Myth 3: "If my insurance covers it, that's automatically my cheapest option."

Usually, but not always. With a high deductible early in the plan year, or a high-tier placement, your "covered" cost can exceed the manufacturer-direct cash price. Always compare the two for your specific plan rather than assuming covered wins.

Myth 4: "Medicare doesn't cover weight-loss drugs."

That was true for years, but changed in 2026 with the GLP-1 Bridge, which covers eligible enrollees at a $50 copay. It's specific and time-limited, but the blanket "Medicare never covers these" is now outdated.

Myth 5: "The advertised price is what I'll pay."

Often it's a starter or intro price for the first fill or two, or a price at the lowest dose, that steps up. The number that matters is your ongoing cost at your maintenance dose. Treating the teaser as the real price is how people get surprised at month four.

Myth 6: "Prices will keep rising, so lock in now."

The 2026 trend is the opposite — competition and direct sales are pushing prices down, and more cheap-to-make pills are coming. Locking into a long prepay on a single product can be a bet against your own future options in a falling market. Flexibility is usually worth more than a lock-in discount right now.

Myth 7: "There's one cheapest way to get a GLP-1."

There isn't a universal answer — the cheapest route is different for the insured employee, the Medicare enrollee, the uninsured self-payer and the person with diabetes, and it can be any of a copay, $50, a few hundred dollars direct, or a compounded price. Anyone who tells you "the cheapest way is X" without asking about your coverage is guessing. The cheapest route is the one that matches your specific situation, which is why this guide is organized around situations rather than a single verdict.

Frequently asked questions

How much does Wegovy cost in 2027?

It depends on your route. With insurance that covers it, you may pay a copay as low as $0–$50/mo. Self-pay direct from the manufacturer, the Wegovy pill runs from about $149/mo (rising with dose) and the injection around $349/mo, with a lower starter offer near $199/mo for the first couple of fills through the end of 2026. Eligible Medicare enrollees can pay a $50 copay via the GLP-1 Bridge. The old $1,000-plus list price is avoidable for anyone who uses a direct option. Confirm current pricing at NovoCare.

How much does Zepbound cost without insurance?

Direct self-pay from the manufacturer, Zepbound vials start around $299/mo at the lowest dose and rise with dose into roughly the $400–$700 range at higher strengths. Eligible Medicare enrollees can access the KwikPen for a $50 copay through the Bridge. Check the official Zepbound site for current figures, since prices and offers change.

Does Medicare cover Ozempic or Wegovy for weight loss now?

For weight loss specifically, Medicare historically didn't — but in 2026 the Medicare GLP-1 Bridge began covering weight-loss GLP-1s (including Wegovy and Zepbound's KwikPen, and the Foundayo pill) for eligible Part D enrollees at a $50 monthly copay. It started July 1, 2026, requires prior authorization and specific eligibility, and is a time-limited demonstration, so confirm current details with CMS and your plan. Diabetes coverage for Ozempic/Mounjaro is separate and longer-standing.

What is the Medicare GLP-1 Bridge?

It's a federal demonstration program from CMS that lets eligible Medicare Part D enrollees get covered weight-loss GLP-1s for a $50 monthly copay, launched July 1, 2026. It covers the Wegovy pill and injection, the Zepbound KwikPen, and Foundayo, when prescribed for weight management. The $50 generally doesn't count toward your Part D deductible or out-of-pocket max, eligibility is specific (obesity or overweight-plus-a-condition, prior authorization required), and it's a pilot with a time limit — verify current status with CMS.

What's the cheapest way to get a GLP-1 in 2027?

If you have insurance that covers it, a copay beats everything — confirm 2027 coverage and clear prior authorization. If you're on Medicare and eligible, the $50 Bridge copay is likely your floor. If you're self-pay, the oral options (Wegovy pill, Foundayo) are the cheapest branded entry (from ~$149/mo), with legitimate compounded sometimes a bit less but on narrower legal footing. The cheapest route is situation-specific — work through our "by situation" section.

My employer dropped GLP-1 coverage — what do I do?

First, don't panic: the 2026 price drops mean losing coverage is far less costly than it used to be. Check whether a diabetes indication applies to you (that coverage is often retained), price the manufacturer-direct route (a few hundred a month for branded, less for pills), look at the Medicare Bridge if you're eligible, and use savings cards. The step from a low copay to direct self-pay is real but it's hundreds of dollars, not the thousand-dollar cliff of a year ago.

Why is employer GLP-1 coverage being cut?

Cost. These drugs are expensive in aggregate, demand is high, and people take them long-term, which strains self-insured employers' budgets. In 2026 the share of companies covering GLP-1s for weight loss declined for the first time, and some that still cover them are weighing exits or adding hurdles like prior authorization and BMI thresholds. Diabetes coverage for the same molecules is generally more stable.

Is compounded semaglutide still cheaper than branded?

Often a little, but the gap shrank dramatically. When branded direct prices fell to a few hundred dollars a month in 2026, the compounded discount stopped being a chasm. A compounded program at $149–$199 versus a branded drug at $299–$349 is comparable territory, and the branded product adds FDA oversight and consistent dosing. Compounded also now sits on narrower legal footing since the shortage ended — see our compounded-legality guide. The old "compounded is far cheaper" assumption no longer holds automatically.

How much does the Wegovy pill cost?

The oral Wegovy pill (oral semaglutide 25 mg for weight management) runs from about $149/mo at the lowest dose up to around $299 at higher strengths, self-pay direct from the manufacturer — the cheapest branded entry point. Insurance or the Medicare Bridge can drop it to a copay.

How much does Foundayo (orforglipron) cost?

Foundayo, the newer oral GLP-1, is priced in a similar self-pay range to the other pill and is covered under the Medicare Bridge. As a small-molecule drug that's cheaper to manufacture, it has the strongest long-term case for falling prices.

Does insurance still cover GLP-1s for weight loss in 2027?

Some plans do, but it's exactly what's shrinking — roughly half of employers covered weight-loss GLP-1s in 2026, down for the first time, with more hurdles being added. Don't assume last year's coverage carries into 2027; check your specific 2027 formulary during open enrollment, including the tier and any prior-authorization requirement. Diabetes coverage for the same drugs is generally firmer.

Why are GLP-1 prices dropping?

A mix of competition and policy. The manufacturers began selling direct to patients at much lower self-pay prices, a federal direct-purchase channel launched, more approved drugs (including cheaper-to-make pills) entered the market, and deals lowered the price Medicare pays. Together those pushed the effective price of a GLP-1 from $1,000-plus toward a few hundred dollars for self-pay buyers.

Do I need prior authorization?

If you're going through insurance (commercial or the Medicare Bridge), usually yes — the insurer wants documentation that you meet their criteria (typically BMI, sometimes a weight-related condition). Self-pay direct and compounded routes don't involve prior authorization. If you're denied, appeal: denials are frequently overturned with proper documentation, and giving up at the first "no" costs people covered drugs they qualify for.

Is the $50 Medicare GLP-1 price real?

Yes, for those who qualify — it's the copay under the Medicare GLP-1 Bridge demonstration that began in 2026. The catches are that eligibility is specific, prior authorization is required, the $50 generally doesn't count toward your deductible or out-of-pocket max, and it's a time-limited pilot. Confirm your eligibility and the program's current end date with CMS.

Should I switch from compounded to branded now that prices dropped?

For many people, it's worth re-running the numbers. With branded direct prices down and compounded's legal footing narrowed, the trade-off shifted — a modestly higher branded price now buys FDA approval, consistent dosing and a fixed-dose pen. If you have a genuine clinical reason for compounding, or you're on a tight budget with no coverage, legitimate compounded can still make sense. Otherwise, the 2026 price drops made branded the stronger default for a lot of buyers.

Are the direct/self-pay prices the same as going through insurance?

No. Self-pay direct prices (from the manufacturer or a federal direct site) don't run through your insurance, so they don't count toward your deductible or out-of-pocket maximum. If your plan would eventually cover the drug after you meet the deductible, paying cash on the side can mean you don't get credit for it. If you have no coverage for the drug, self-pay direct is simply the price. Do the math for your specific plan.

What about Ozempic and Mounjaro for weight loss?

They're the same molecules as Wegovy and Zepbound but branded for type 2 diabetes, not approved for weight loss. If you have diabetes, their coverage is often firmer and more affordable than the weight-loss brands, and the weight benefit comes along. Using a diabetes brand purely for weight loss is a clinical decision for your prescriber, and coverage for that use is unreliable.

How often do these prices change?

Frequently in 2026 — promos expire (the Wegovy starter is tied to end-2026), doses change your tier, and the overall market is trending down. Treat any price, including those in this guide, as a snapshot, confirm it at the source before buying, and re-check every few months, because re-shopping genuinely pays in a falling market.

Where can I compare programs on real price?

Our ranked comparison shows each online program's real monthly cost at a maintenance dose — not the intro teaser — alongside its medication options and support, which is the comparison that actually predicts your bill. Pair it with our what you'll really pay guide and our methodology.

Will GLP-1 prices go down in 2027?

The late-2026 trend points down. Competition (more drugs, two makers, the pills), direct-to-consumer sales that bypass rebates, and deals lowering the price Medicare pays are all pushing the same direction, and cheaper-to-make oral drugs like Foundayo add downward pressure. Nobody can promise specific future prices, and coverage remains a wild card, but the thousand-dollar GLP-1 is already effectively gone for anyone who shops, and the floor is still easing.

Can I use my HSA or FSA to pay for a GLP-1?

Generally yes, when the medication is prescribed for a diagnosed condition — HSA and FSA funds typically cover prescription GLP-1s, including self-pay and direct-purchase costs, which effectively gives you a tax discount on the price. Rules have nuances (a prescription and sometimes a letter of medical necessity help), so confirm with your plan administrator. Using pre-tax dollars is one of the simpler ways to cut your real cost that people overlook.

How do I appeal a GLP-1 insurance denial?

Ask your prescriber's office to file an appeal with full documentation — your BMI, any weight-related conditions (high blood pressure, prediabetes, sleep apnea), and records of prior weight-loss attempts, which is often what the insurer wants to see. Many first denials are overturned on appeal. There are usually internal and then external review levels; don't stop at the first "no," because a successful appeal can unlock a copay price that beats every self-pay route.

Are LillyDirect and NovoCare legitimate?

Yes — they're the drug makers' own official direct-to-patient channels (Lilly's and Novo Nordisk's, respectively) for buying their FDA-approved GLP-1s at a set self-pay price, and they're among the safest ways to buy. The caution is impostor sites: reach them from the manufacturer's known domain rather than an ad or uncertain search result, and remember a legitimate channel still requires a prescription.

What's the difference between the list price and what I'll pay?

The list price (the $1,000-plus figure) is the sticker before any insurance, rebate, savings program or direct discount — and almost nobody pays it now. What you'll actually pay is set by your channel: a copay with coverage, $50 via the Medicare Bridge if eligible, or a few hundred dollars through manufacturer-direct self-pay. Judge an offer by its absolute price at your dose, not by how big a "discount off list" it claims, because list was always fiction for most buyers.

Can a telehealth program be cheaper than my insurance?

Sometimes, yes — especially early in a plan year before you've met a high deductible, or if your plan puts the drug on a high tier. Self-pay direct or a legitimate program can undercut a "covered" price in those cases. The only way to know is to compare your real covered cost (tier copay, deductible status, prior-auth hurdles) against the direct cash price for your specific situation. Run both numbers rather than assuming insurance always wins.

What happens to my price when my dose increases?

For many pricing tiers, it goes up — GLP-1s are titrated upward over months, and both branded direct pricing and some compounded plans charge more at higher doses. A price quoted at the starting dose can be meaningfully higher at the maintenance dose that actually works for you. Always ask what the top-dose price is before committing, and budget for the maintenance figure, not the starter.

Does GoodRx or a discount card help with GLP-1 costs?

Discount cards can help in some cases, but with manufacturer-direct self-pay prices now low and manufacturer savings cards available for insured patients, the direct and manufacturer-savings routes are often the better starting point for GLP-1s specifically. Compare a discount-card price against the manufacturer-direct price before assuming the card is cheapest — for these drugs, it frequently isn't the lowest option anymore.

A plain-language glossary

• Self-pay / cash price: what you pay without using insurance. Manufacturer-direct and compounded prices are self-pay and don't count toward your deductible.
• Copay: your share of a drug's cost when insurance covers it — often $0–$50/mo for a covered GLP-1, or the flat $50 under the Medicare Bridge.
• Prior authorization: documentation an insurer requires (usually BMI and related conditions) before covering a drug. Denials can often be appealed successfully.
• Medicare GLP-1 Bridge: the 2026 CMS demonstration giving eligible Part D enrollees covered weight-loss GLP-1s for a $50 copay.
• Manufacturer direct (NovoCare / LillyDirect): buying the FDA-approved drug straight from the maker's pharmacy channel at a set self-pay price.
• Starter / intro price: a lower price for the first fill or two that then steps up — not your ongoing cost.
• Maintenance dose: the dose you settle on long-term; the price here is the one that matters, since GLP-1s are titrated up over months.
• Compounded: a pharmacy-prepared version, not FDA-approved; historically the cheapest route, now a narrower legal lane and a smaller discount.
• List price: the headline price before any insurance, savings or direct program — the $1,000-plus figure almost nobody needs to pay now.

How we sourced this, and a note on accuracy

Prices and programs in this guide reflect the landscape as of late 2026, drawn from the manufacturers' official cost information (NovoCare for Wegovy and the official Zepbound site for Zepbound), the Centers for Medicare & Medicaid Services for the GLP-1 Bridge and general Medicare coverage, and reporting on employer-coverage trends. Because this is a fast-moving pricing and policy story, we've given ranges and flagged promotional expiry dates rather than implying any figure is permanent — and the single most important instruction in this whole guide is to confirm the current price at the official source for your specific drug, dose and plan before you buy. We don't sell medication or prescribe; we track prices so you can compare honestly.

The bottom line

The GLP-1 affordability story flipped in 2026. For three years the problem was a thousand-dollar drug and a coin-flip of coverage; now the problem is a fragmented, fast-changing set of channels where the same medication ranges from a $0 copay to $700 depending on how you buy it. Employer coverage is pulling back, which is the scary headline — but the direct prices collapsed and Medicare stepped in at the same time, which is the reassuring reality underneath it. For most people, an effective GLP-1 is more affordable and more accessible at the end of 2026 than it was at the start, not less.

What hasn't changed is the thing we've said since day one: the price that matters is the real monthly cost at the dose you stay on, through the channel that fits your situation — not the teaser, not the list price, not last year's number. The people who overpay in this market are the ones who assume the old prices still apply or set up autopay and stop looking. The people who pay the least are the ones who know the channels, check their specific situation, and re-shop as the market keeps moving. This guide is the map; your next move is to price your own situation with current numbers, and our ranked comparison and complete guide are built to help you do exactly that.